#1 Clinical Trials Search in Europe

Ly3473329

Clinical trials are studying Ly3473329 in adults with elevated lipoprotein(a), also called Lp(a), who are at high risk for cardiovascular events. These trials mainly look at safety and how well the treatment works. The main study in the data is a Phase 2 trial in adult participants.

Table of contents

Trial overview

The main clinical trial in the data studied Ly3473329 in adults with elevated lipoprotein(a), also written as Lp(a), who were at high risk for cardiovascular events.[1] The study was designed to evaluate both efficacy and safety, meaning it looked at whether the treatment helped and whether it could be used safely in the study group.[1]

Who was studied

The trial focused on adult participants with elevated Lp(a).[1] These participants were also described as being at high risk for cardiovascular events, which means they had a greater chance of serious heart or blood vessel problems.[1]

Study design and treatment groups

This was an interventional study, so participants received a study treatment rather than only being observed.[1] The listed interventions included Ly3473329 at 240 mg taken orally and a placebo made to match Ly3473329.[1] A placebo is a look-alike treatment with no active medicine, used so researchers can compare results fairly.[1]

What was measured

The main outcome was the percent change from baseline in Lp(a) from the start of the study to Week 12.[1] Baseline means the first measurement before treatment begins, and percent change shows how much the level went up or down over time.[1] This endpoint helps researchers see whether Ly3473329 changes Lp(a) levels in the study participants.[1]

Trial status and size

The trial status is listed as Completed.[1] A total of 233 people were enrolled, which means 233 participants joined the study.[1] The study was a Phase 2 trial, a stage that usually looks more closely at whether a treatment works while continuing safety checks.[1]

What this means for patients

For patients, this trial is important because it targets a blood marker, Lp(a), that is linked to cardiovascular risk.[1] The study was not a general health study; it was focused on adults with a specific lipoprotein disorder and higher heart risk.[1] The results were planned to show whether Ly3473329 could lower Lp(a) over 12 weeks in this group.[1]

Trial ID Phase Condition studied Status Enrollment Main outcome
2022-501466-21-00 Phase 2 Elevated lipoprotein(a) in adults at high risk for cardiovascular events Completed 233 Percent change from baseline in Lp(a) to Week 12

FAQ

  • What is being studied in the Ly3473329 trials? The trials are studying Ly3473329 in adults with elevated lipoprotein(a), or Lp(a). The main goal is to see if it can lower Lp(a) and whether it is safe.
  • Who can take part in these trials? The main trial includes adult participants with elevated Lp(a) who are at high risk for cardiovascular events. This means the study is focused on adults with a higher chance of heart or blood vessel problems.
  • What phase is the Ly3473329 trial? The trial listed in the data is a Phase 2 study. Phase 2 trials usually look more closely at whether a treatment works and continue safety checks.
  • What condition is being targeted? The trial targets a lipoprotein disorder, specifically elevated lipoprotein(a) levels. Lp(a) is a blood fat-related marker linked to cardiovascular risk.
  • What is the main outcome being measured? The main outcome is the percent change from baseline in Lp(a) from the start of the study to Week 12. This helps show whether Ly3473329 changes Lp(a) levels over time.

Ongoing Clinical Trials on Ly3473329

  • Study of LY3473329 for Adults with High Lipoprotein(a) Levels at Risk for Heart Problems

    Not recruiting

    1
    Investigated diseases:
    Investigated drugs:
    Germany Hungary The Netherlands

Glossary

  • Lipoprotein(a) (Lp(a)): A type of blood particle related to cholesterol. High levels are linked with a greater risk of heart and blood vessel problems.
  • Cardiovascular events: Serious problems affecting the heart or blood vessels, such as a heart attack or stroke.
  • Phase 2: A mid-stage clinical trial that looks at whether a treatment works and continues to check safety.
  • Interventional study: A study where participants are given a treatment so researchers can measure its effects.
  • Placebo: A treatment that looks like the study drug but has no active medicine. It is used for comparison.
  • Baseline: The first measurement taken before treatment starts. Later results are compared with this starting point.
  • Percent change from baseline: How much a measurement goes up or down compared with the starting value, shown as a percentage.
  • Enrollment: The number of people who joined the study.
  • Completed: The study has finished and the planned trial activities are done.
  • Adult participants: People who are 18 years old or older and took part in the study.

References

  1. https://clinicaltrials.gov/study/2022-501466-21-00